Launched 3DC-incubated Boulevard Bio with $65M from Deerfield and a precision-immunology pipeline led by BLVD101.
Boulevard Bio is a clinical-stage, precision immunology company built to change the course of B cell-driven autoimmune diseases with targeted multi-specific medicines designed to set new therapeutic standards
Boulevard Bio is a clinical-stage, precision immunology company built to change the course of B cell-driven autoimmune diseases with targeted multi-specific medicines designed to set new therapeutic standards. Their approach is grounded in a deep understanding of B cell biology, aiming to modify disease at its source with innovative therapies.